Home » Boehringer Releases Positive Results From Two Breast Cancer Trials of Afatinib

Boehringer Releases Positive Results From Two Breast Cancer Trials of Afatinib

December 15, 2014

Germany-based Boehringer Ingelheim has reported positive results from two trials (LUX-Breast 1 and LUX-Breast 3) evaluating afatinib to treat patients with breast cancer.
Pharmaceutical Business Review

04Apr
Optimizing Quality Control Operations with Unified Quality
20Apr
Medical Device Enforcement: Latest Developments from the FDA, DOJ and FTC
25Apr
Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials
26Apr
FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know
27Apr
Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis
17May
2023 WCG Avoca Quality Consortium Summit

Boehringer Releases Positive Results From Two Breast Cancer Trials of Afatinib

Upcoming Events

Optimizing Quality Control Operations with Unified Quality

Medical Device Enforcement: Latest Developments from the FDA, DOJ and FTC

Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

2023 WCG Avoca Quality Consortium Summit

Featured Products

FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

GrayMatters Health’s Digital Therapy Device for PTSD Cleared

Dupixent Shows Positive Results in COPD Study

Advamedica’s Hemostat Cleared for Severe Surgical Bleeding

FDA Approves Sandoz’s Citrate-Free Adalimubab Formulation

The Revised ICH E8: A Guide to New Clinical Trial Requirements